Compare Applied Digital Corporation (APLD) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applied Digital Corporation vs Crispr Therapeutics AG — how do they compare? Applied Digital Corporation trades at $30.63 (market cap $8.90B), while Crispr Therapeutics AG trades at $53.25 (market cap $5.25B). The key difference: Applied Digital Corporation is the larger of the two by market cap, and Applied Digital Corporation is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| APLD | CRSP | |
|---|---|---|
Market Cap | $8.90B | $5.25B |
Sector | Technology | Health |
52-Week High | $49.65 | $76.78 |
52-Week Low | $9.18 | $44.34 |
Enterprise Value | $10.00B | $3.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Digital (APLD) trades at $31.15, down 3.53% today, amid bearish technical signals despite unanimous analyst buy ratings. The company shows strong revenue growth with $144M in 2025 and $319M projected for 2026, but remains unprofitable with negative margins. Recent news highlights APLD's pivot to AI data centers with $36B in contracted lease value, though execution risks and customer concentration persist.
Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and heavy capital spending. Risks include customer concentration and debt load, but analyst consensus targets $76.67 suggest significant upside if execution improves.
CRISPR Therapeutics (CRSP) trades at $53.35, down 5.31% on the day, with technical indicators showing a bullish trend but mixed earnings performance. The company maintains strong analyst support with a $74.50 consensus price target, despite negative profitability metrics and recent quarterly misses. Recent FDA pediatric approval for Casgevy expands its market potential, though cash flow remains challenged by high operational costs.
Outlook is cautiously optimistic driven by gene-editing leadership and clinical catalysts, but investment carries high risk due to persistent losses, volatile cash flows, and competitive pressures. Upside depends on successful commercialization and pipeline execution, while downside risks include funding needs and regulatory hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Digital Corporation
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
